1. Home
  2. INCY
  3. INCY News

Latest Incyte Corp. (INCY) News on June 21, 2025

INCY

MT Newswires

a day ago

Incyte Says FDA Extends Review Period for Ruxolitinib Cream

Update on FDA Review of Ruxolitinib Cream (Opzelura®) for Children Ages 2-11 with Atopic Dermatitis
INCY

Business Wire

a day ago

Update on FDA Review of Ruxolitinib Cream (Opzelura®) for Children Ages 2-11 with Atopic Dermatitis

Incyte (INCY) Teams Up with QIAGEN to Boost Blood Cancer Diagnostic Solutions
INCY

Insider Monkey

a day ago

Incyte (INCY) Teams Up with QIAGEN to Boost Blood Cancer Diagnostic Solutions

Incyte Gets FDA Nod for the Expanded Use of Monjuvi in Lymphoma
INCY

Zacks

2 days ago

Incyte Gets FDA Nod for the Expanded Use of Monjuvi in Lymphoma

INCY

MT Newswires

3 days ago

Incyte's Drug to Treat Follicular Lymphoma Receives FDA Approval

Incyte Announces FDA Approval of Monjuvi® (tafasitamab-cxix) in Combination with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma
INCY

Business Wire

3 days ago

Incyte Announces FDA Approval of Monjuvi® (tafasitamab-cxix) in Combination with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma

Incyte And Two Other Stocks That May Be Priced Below Their Estimated Value
INCY

Simply Wall St.

4 days ago

Incyte And Two Other Stocks That May Be Priced Below Their Estimated Value

Incyte Stock Rises on QIAGEN Deal to Advance Blood Cancer Diagnostics
INCY

Zacks

4 days ago

Incyte Stock Rises on QIAGEN Deal to Advance Blood Cancer Diagnostics

Cisco upgraded, CoreWeave downgraded: Wall Street’s top analyst calls
INCY

TipRanks

4 days ago

Cisco upgraded, CoreWeave downgraded: Wall Street’s top analyst calls

3 Unpopular Stocks in Hot Water
INCY

StockStory

5 days ago

3 Unpopular Stocks in Hot Water

INCY

MT Newswires

5 days ago

Sector Update: Health Care Stocks Flat to Higher Premarket Monday

QGEN Stock Rises in After Market Following Partnership With Incyte
INCY

Zacks

5 days ago

QGEN Stock Rises in After Market Following Partnership With Incyte

Qiagen and Incyte to develop diagnostic panel for myeloproliferative neoplasms
INCY

Medical Device Network

5 days ago

Qiagen and Incyte to develop diagnostic panel for myeloproliferative neoplasms

INCY

MT Newswires

5 days ago

Stifel Upgrades Incyte to Buy From Hold, Adjusts Price Target to $107 From $75

INCY

MT Newswires

5 days ago

Jefferies Adjusts Price Target on Incyte to $82 From $76, Maintains Buy Rating

INCY

MT Newswires

6 days ago

QIAGEN, Incyte Partner to Develop NGS-Based Diagnostic Panel for Rare Blood Cancers

INCY

MT Newswires

6 days ago

Incyte Says 86% of Blood Cancer Patients Responsive to Higher Doses of Drug Candidate

Incyte (INCY) Targets $1B Growth by 2029 with New Drug Launches
INCY

Insider Monkey

6 days ago

Incyte (INCY) Targets $1B Growth by 2029 with New Drug Launches

QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs)
INCY

Business Wire

7 days ago

QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs)

Positive Late-Breaking Data for Incyte’s First-in-Class mutCALR-targeted therapy INCA033989 in Essential Thrombocythemia Presented at EHA2025
INCY

Business Wire

7 days ago

Positive Late-Breaking Data for Incyte’s First-in-Class mutCALR-targeted therapy INCA033989 in Essential Thrombocythemia Presented at EHA2025

Specialised Therapeutics announces expanded partnership with Incyte
INCY

TipRanks

8 days ago

Specialised Therapeutics announces expanded partnership with Incyte

Phase 3 Data for Incyte’s Retifanlimab (Zynyz®) in Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) Published in The Lancet
INCY

Business Wire

9 days ago

Phase 3 Data for Incyte’s Retifanlimab (Zynyz®) in Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) Published in The Lancet

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
INCY

Business Wire

15 days ago

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Qiagen (QGEN) Up 8.1% Since Last Earnings Report: Can It Continue?
INCY

Zacks

15 days ago

Qiagen (QGEN) Up 8.1% Since Last Earnings Report: Can It Continue?

Why Is Halozyme Therapeutics (HALO) Down 23.2% Since Last Earnings Report?
INCY

Zacks

16 days ago

Why Is Halozyme Therapeutics (HALO) Down 23.2% Since Last Earnings Report?

US High Growth Tech Stocks To Watch In June 2025
INCY

Simply Wall St.

17 days ago

US High Growth Tech Stocks To Watch In June 2025

Incyte Announces Multiple Presentations, Including New Late-Breaking Data for its mutCALR-Directed Monoclonal Antibody (INCA033989), Accepted for Presentation at EHA 2025
INCY

Business Wire

18 days ago

Incyte Announces Multiple Presentations, Including New Late-Breaking Data for its mutCALR-Directed Monoclonal Antibody (INCA033989), Accepted for Presentation at EHA 2025

INCY

Morningstar Research

23 days ago

Analyst Report: Incyte Corporation

Why Is Incyte (INCY) Up 3.6% Since Last Earnings Report?
INCY

Zacks

23 days ago

Why Is Incyte (INCY) Up 3.6% Since Last Earnings Report?

Incyte to Present at Upcoming Investor Conference
INCY

Business Wire

25 days ago

Incyte to Present at Upcoming Investor Conference

INCY

MT Newswires

25 days ago

Truist Securities Adjusts Price Target on Incyte to $73 From $72, Maintains Hold Rating

3 Reasons INCY is Risky and 1 Stock to Buy Instead
INCY

StockStory

a month ago

3 Reasons INCY is Risky and 1 Stock to Buy Instead

3 Mid-Cap Stocks with Questionable Fundamentals
INCY

StockStory

a month ago

3 Mid-Cap Stocks with Questionable Fundamentals

FDA approves Incyte’s retifanlimab combo for SCAC treatment
INCY

Pharmaceutical Technology

a month ago

FDA approves Incyte’s retifanlimab combo for SCAC treatment

Incyte Gets FDA Approval for Zynyz in New Cancer Indication
INCY

Zacks

a month ago

Incyte Gets FDA Approval for Zynyz in New Cancer Indication

INCY

MT Newswires

a month ago

Leerink Partners Adjusts Incyte Price Target to $96 From $95

INCY

MT Newswires

a month ago

Incyte Says FDA Approves Zynyz for Anal Cancer Treatment

INCY

MT Newswires

a month ago

Argus Lowers Price Target on Incyte to $75 From $80

Incyte Announces FDA Approval of Zynyz® (retifanlimab-dlwr) Making it the First and Only Approved First-Line Treatment for Advanced Anal Cancer Patients in the United States
INCY

Business Wire

a month ago

Incyte Announces FDA Approval of Zynyz® (retifanlimab-dlwr) Making it the First and Only Approved First-Line Treatment for Advanced Anal Cancer Patients in the United States

INCY

Argus Research

a month ago

Analyst Report: Incyte Corp.

INCY

Argus Research

a month ago

Market Update: CSCO, FCX, INCY, XRX, SMCI

INCY

MT Newswires

a month ago

Incyte to Pay Novartis $280 Million to Resolve Jakafi Royalties Dispute

Incyte Corporation (INCY): Among Small-Cap Healthcare Stocks Hedge Funds Are Buying
INCY

Insider Monkey

a month ago

Incyte Corporation (INCY): Among Small-Cap Healthcare Stocks Hedge Funds Are Buying

INCY Q1 Earnings Call: New Product Launches and Pipeline Progress Drive Outperformance
INCY

StockStory

a month ago

INCY Q1 Earnings Call: New Product Launches and Pipeline Progress Drive Outperformance

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
INCY

Business Wire

a month ago

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

What To Expect From Natera’s (NTRA) Q1 Earnings
INCY

StockStory

a month ago

What To Expect From Natera’s (NTRA) Q1 Earnings

INCY

Thomson Reuters StreetEvents

2 months ago

Q1 2025 Syndax Pharmaceuticals Inc Earnings Call

INCY

MT Newswires

2 months ago

Mizuho Adjusts Price Target on Incyte to $70 From $77, Maintains Neutral Rating

High Growth Tech Stocks in US with Strong Potential for Investors
INCY

Simply Wall St.

2 months ago

High Growth Tech Stocks in US with Strong Potential for Investors

Incyte to Present at Upcoming Investor Conference
INCY

Business Wire

2 months ago

Incyte to Present at Upcoming Investor Conference

INCY

MT Newswires

2 months ago

Leerink Partners Raises Price Target on Incyte to $95 From $92

INCY

MT Newswires

2 months ago

Stifel Lowers Price Target on Incyte to $75 From $77

INCY

MT Newswires

2 months ago

TD Cowen Lowers Price Target on Incyte to $86 From $88

INCY

MT Newswires

2 months ago

Morgan Stanley Adjusts Incyte's Price Target to $68 From $65

INCY

MT Newswires

2 months ago

RBC Raises Price Target on Incyte to $67 From $64, Keeps Sector Perform Rating

Incyte First Quarter 2025 Earnings: Beats Expectations
INCY

Simply Wall St.

2 months ago

Incyte First Quarter 2025 Earnings: Beats Expectations

Incyte Corp (INCY) Q1 2025 Earnings Call Highlights: Robust Revenue Growth and Strategic ...
INCY

GuruFocus.com

2 months ago

Incyte Corp (INCY) Q1 2025 Earnings Call Highlights: Robust Revenue Growth and Strategic ...

INCY

Morningstar Research

2 months ago

Analyst Report: Incyte Corporation

INCY

MT Newswires

2 months ago

Wells Fargo Hikes Price Target on Incyte to $59 From $58

INCY

MT Newswires

2 months ago

Jefferies Adjusts Incyte Price Target to $76 From $75

INCY Q1 Earnings & Revenues Beat Estimates on Higher Product Sales
INCY

Zacks

2 months ago

INCY Q1 Earnings & Revenues Beat Estimates on Higher Product Sales

Here's What Key Metrics Tell Us About Incyte (INCY) Q1 Earnings
INCY

Zacks

2 months ago

Here's What Key Metrics Tell Us About Incyte (INCY) Q1 Earnings

3 Value Stocks Facing Headwinds
INCY

StockStory

2 months ago

3 Value Stocks Facing Headwinds

Incyte (INCY) Q1 Earnings and Revenues Top Estimates
INCY

Zacks

2 months ago

Incyte (INCY) Q1 Earnings and Revenues Top Estimates

INCY

MT Newswires

2 months ago

Incyte Q1 Adjusted Earnings, Revenue Rise

Incyte (NASDAQ:INCY) Delivers Strong Q1 Numbers
INCY

StockStory

2 months ago

Incyte (NASDAQ:INCY) Delivers Strong Q1 Numbers

INCY

Associated Press Finance

2 months ago

Incyte: Q1 Earnings Snapshot

Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY

Business Wire

2 months ago

Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs

Incyte (INCY) Q1 Earnings Report Preview: What To Look For
INCY

StockStory

2 months ago

Incyte (INCY) Q1 Earnings Report Preview: What To Look For

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
INCY

Zacks

2 months ago

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises

Incyte to Highlight Early-Stage Oncology Data at American Association for Cancer Research Annual Meeting 2025
INCY

Business Wire

2 months ago

Incyte to Highlight Early-Stage Oncology Data at American Association for Cancer Research Annual Meeting 2025

Blueprint Medicines (BPMC) Expected to Beat Earnings Estimates: Should You Buy?
INCY

Zacks

2 months ago

Blueprint Medicines (BPMC) Expected to Beat Earnings Estimates: Should You Buy?

3 Cash-Heavy Stocks Skating on Thin Ice
INCY

StockStory

2 months ago

3 Cash-Heavy Stocks Skating on Thin Ice

Incyte to Showcase New Data from its Oncology Portfolio at 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
INCY

Business Wire

2 months ago

Incyte to Showcase New Data from its Oncology Portfolio at 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Incyte Gears Up to Report Q1 Earnings: Here's What You Should Know
INCY

Zacks

2 months ago

Incyte Gears Up to Report Q1 Earnings: Here's What You Should Know

Incyte (INCY) Reports Next Week: Wall Street Expects Earnings Growth
INCY

Zacks

2 months ago

Incyte (INCY) Reports Next Week: Wall Street Expects Earnings Growth

INCY

MT Newswires

2 months ago

JPMorgan Adjusts Incyte Price Target to $68 From $70, Maintains Neutral Rating

INCY

MT Newswires

2 months ago

BofA Adjusts Price Target on Incyte to $87 From $86, Keeps Buy Rating

Immuno-Oncology Stocks Q4 In Review: Exact Sciences (NASDAQ:EXAS) Vs Peers
INCY

StockStory

2 months ago

Immuno-Oncology Stocks Q4 In Review: Exact Sciences (NASDAQ:EXAS) Vs Peers

INCY

MT Newswires

2 months ago

Incyte Faces Limited Exposure From Tariffs on Dual Sourcing, UBS Says

Incyte to Report First Quarter Financial Results
INCY

Business Wire

2 months ago

Incyte to Report First Quarter Financial Results

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
INCY

Business Wire

2 months ago

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Immuno-Oncology Stocks Q4 Highlights: Incyte (NASDAQ:INCY)
INCY

StockStory

2 months ago

Immuno-Oncology Stocks Q4 Highlights: Incyte (NASDAQ:INCY)

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
INCY

Zacks

3 months ago

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

Exploring 3 High Growth Tech Stocks In The US Market
INCY

Simply Wall St.

3 months ago

Exploring 3 High Growth Tech Stocks In The US Market

INCY

MT Newswires

3 months ago

RBC Lowers Price Target on Incyte to $64 From $68, Keeps Sector Perform Rating

3 Reasons INCY is Risky and 1 Stock to Buy Instead
INCY

StockStory

3 months ago

3 Reasons INCY is Risky and 1 Stock to Buy Instead

Knight Therapeutics Announces Launch of Minjuvi® (tafasitamab) in Mexico
INCY

GlobeNewswire

3 months ago

Knight Therapeutics Announces Launch of Minjuvi® (tafasitamab) in Mexico

INCY

MT Newswires

3 months ago

Leerink Partners Adjusts Price Target on Incyte to $92 From $100, Maintains Outperform Rating

Why Incyte Stock Was Tanking This Week
INCY

Motley Fool

3 months ago

Why Incyte Stock Was Tanking This Week

1 Healthcare Stock on Our Watchlist and 2 to Brush Off
INCY

StockStory

3 months ago

1 Healthcare Stock on Our Watchlist and 2 to Brush Off

The Zacks Analyst Blog Highlights Sarepta Therapeutics, Incyte, Gilead Sciences and VTv Therapeutics
INCY

Zacks

3 months ago

The Zacks Analyst Blog Highlights Sarepta Therapeutics, Incyte, Gilead Sciences and VTv Therapeutics

Incyte Had a Bad Week. Investors Are Used to It.
INCY

Barrons.com

3 months ago

Incyte Had a Bad Week. Investors Are Used to It.

Biotech Stock Roundup: Patient Death Hits SRPT, INCY Study Data & More
INCY

Zacks

3 months ago

Biotech Stock Roundup: Patient Death Hits SRPT, INCY Study Data & More

Natera (NASDAQ:NTRA) Q4 Earnings: Leading The Immuno-Oncology Pack
INCY

StockStory

3 months ago

Natera (NASDAQ:NTRA) Q4 Earnings: Leading The Immuno-Oncology Pack

Incyte price target lowered to $72 from $74 at Truist
INCY

TipRanks

3 months ago

Incyte price target lowered to $72 from $74 at Truist

INCY

Morningstar Research

3 months ago

Analyst Report: Incyte Corporation

INCY Stock Down on Disappointing Skin Disease Study Data
INCY

Zacks

3 months ago

INCY Stock Down on Disappointing Skin Disease Study Data

Stoke CEO exits; Medicare drug price talks advance
INCY

BioPharma Dive

3 months ago

Stoke CEO exits; Medicare drug price talks advance

INCY

MT Newswires

3 months ago

Guggenheim Downgrades Incyte to Neutral From Buy

Share on Social Networks: